Jonathan Horsnell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jonathan Horsnell has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Alex Simonovic
Department of Cellular Pathology, Berkshire & Surrey Pathology Services, The Royal Surrey Hospital NHS Foundation Trust, University of Surrey, Egerton Road, Guildford GU2 7XX, UK
2 shared publications - Brenda Kobutungi
Molecular Diagnostics, Berkshire & Surrey Pathology Services, The Royal Surrey Hospital NHS Foundation Trust, Egerton Road, Guildford GU2 7XX, UK
2 shared publications - Catherine Faulkes
Molecular Diagnostics, Berkshire & Surrey Pathology Services, The Royal Surrey Hospital NHS Foundation Trust, Egerton Road, Guildford GU2 7XX, UK
2 shared publications Catherine Kendall
2 shared publications- Daniela Costa
Molecular Diagnostics, Berkshire & Surrey Pathology Services, The Royal Surrey Hospital NHS Foundation Trust, Egerton Road, Guildford GU2 7XX, UK
2 shared publications - Elizabeth Clayton
Breast Unit, The Royal Surrey Hospital NHS Foundation Trust, Egerton Road, Guildford GU2 7XX, UK
2 shared publications
Latest Publications
- Open Access
- 23 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (5) , 2616
Breast Cancer Molecular Subtyping in Practice: A Real-World Study of the APIS Breast Cancer Subtyping Assay in a Consecutive Series of Breast Core Biopsies
The APIS Breast Cancer Subtyping Kit is an mRNA-based assessment of the seven parameters including three biomarkers routinely assessed in all the newly diagnosed breast cancers (BC), oestrogen receptor (ER), progesterone receptor (PR) and HER-2 and an additional four genes that create a novel proliferation signature, MKI67, PCNA, CCNA2 and KIF23. Taken together, the data are used to produce a molecular subtype for every sample. The kit was evaluated against the current standard protocol of immunohistochemistry (IHC) and/or in situ hybridisation (ISH) in breast cancer patients. The data were presented at the weekly breast multidisciplinary team (MDT) meeting. A total of 98 consecutive cases of pre-operative breast cancer core biopsies and two core biopsies of nodal metastases yielding 100 cases were assessed. IHC and APIS results were available for 100 and 99 cases. ER was concordant in 97% cases, PR was concordant in 89% and HER-2 results were concordant with IHC/ISH in 100% of the cases. Ki-67 IHC was discordant in 3% of cases when compared with MK167 alone but discordant in 24% when compared with the four-gene proliferation signature. In conclusion, our study indicates that the APIS Breast Cancer Subtyping Kit is highly concordant when compared to the results produced for ER/PR/HER-2 by IHC and/or ISH. The assay could play a role in the routine assessment of newly diagnosed breast cancer (BC) specimens.
- 23 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (5) , 2616
Open AccessBreast Cancer Molecular Subtyping in Practice: A Real-World Study of the APIS Breast Cancer Subtyping Assay in a Consecutive Series of Breast Core Biopsies
The APIS Breast Cancer Subtyping Kit is an mRNA-based assessment of the seven parameters including three biomarkers routinely assessed in all the newly diagnosed breast cancers (BC), oestrogen receptor (ER), progesterone receptor (PR) and HER-2 and an additional four genes that create a novel proliferation signature, MKI67, PCNA, CCNA2 and KIF23. Taken together, the data are used to produce a molecular subtype for every sample. The kit was evaluated against the current standard protocol of immunohistochemistry (IHC) and/or in situ hybridisation (ISH) in breast cancer patients. The data were presented at the weekly breast multidisciplinary team (MDT) meeting. A total of 98 consecutive cases of pre-operative breast cancer core biopsies and two core biopsies of nodal metastases yielding 100 cases were assessed. IHC and APIS results were available for 100 and 99 cases. ER was concordant in 97% cases, PR was concordant in 89% and HER-2 results were concordant with IHC/ISH in 100% of the cases. Ki-67 IHC was discordant in 3% of cases when compared with MK167 alone but discordant in 24% when compared with the four-gene proliferation signature. In conclusion, our study indicates that the APIS Breast Cancer Subtyping Kit is highly concordant when compared to the results produced for ER/PR/HER-2 by IHC and/or ISH. The assay could play a role in the routine assessment of newly diagnosed breast cancer (BC) specimens.
- Open Access
- 12 January 2024
- Published by MDPI AG in Preprints.org
Breast Cancer Molecular Subtyping in Practice: A Real-World Study of the APIS Breast Cancer Subtyping Assay in a Consecutive Series of Breast Core Biopsies
The APIS Breast Cancer Subtyping Kit is an mRNA-based assessment of the three biomarkers routinely assessed in all newly diagnosed breast cancers (BC), estrogen receptor (ER), progesterone receptor (PR), and HER2 as well as an additional four genes that create a novel proliferation signature, MKI67, PCNA, CCNA2, KIF23. Taken together the data is used to produce a molecular sub-type for every sample. The kit was evaluated against the current standard protocol of immunohistochemistry (IHC) and/or in situ hybridization (ISH) in breast cancer patients. The data was presented at the weekly breast Multidisciplinary Team (MDT) meeting. 98 consecutive cases of pre-operative breast cancer core biopsies and two core biopsy of nodal metastases yielding 100 cases were assessed. IHC and APIS Results were available for 100 and 99 cases. ER was concordant in 97% cases, PR in 89% and HER2 results were concordant with IHC/ISH in 100% of the cases. Ki-67 IHC was discordant in 3% cases when compared with MK167 alone but discordant in 24% when compared with the four gene proliferation signature. In conclusion, our study, indicates that the APIS Breast Cancer Subtyping Kit is highly concordant when compared to the results produced for ER/PR/HER2 by IHC and/or ISH. The assay could play a role in the routine assessment of newly diagnoses Breast Cancer (BC) specimens.
- 12 January 2024
- Published by MDPI AG in Preprints.org
Open AccessBreast Cancer Molecular Subtyping in Practice: A Real-World Study of the APIS Breast Cancer Subtyping Assay in a Consecutive Series of Breast Core Biopsies
The APIS Breast Cancer Subtyping Kit is an mRNA-based assessment of the three biomarkers routinely assessed in all newly diagnosed breast cancers (BC), estrogen receptor (ER), progesterone receptor (PR), and HER2 as well as an additional four genes that create a novel proliferation signature, MKI67, PCNA, CCNA2, KIF23. Taken together the data is used to produce a molecular sub-type for every sample. The kit was evaluated against the current standard protocol of immunohistochemistry (IHC) and/or in situ hybridization (ISH) in breast cancer patients. The data was presented at the weekly breast Multidisciplinary Team (MDT) meeting. 98 consecutive cases of pre-operative breast cancer core biopsies and two core biopsy of nodal metastases yielding 100 cases were assessed. IHC and APIS Results were available for 100 and 99 cases. ER was concordant in 97% cases, PR in 89% and HER2 results were concordant with IHC/ISH in 100% of the cases. Ki-67 IHC was discordant in 3% cases when compared with MK167 alone but discordant in 24% when compared with the four gene proliferation signature. In conclusion, our study, indicates that the APIS Breast Cancer Subtyping Kit is highly concordant when compared to the results produced for ER/PR/HER2 by IHC and/or ISH. The assay could play a role in the routine assessment of newly diagnoses Breast Cancer (BC) specimens.
- 6 May 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (5) , e226-e227
10 years of changing trends in reconstructive choices in patients presenting to the Guildford gene carrier clinic
- 6 May 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (5) , e226-e227
10 years of changing trends in reconstructive choices in patients presenting to the Guildford gene carrier clinic
- 1 October 2017
- Published by Elsevier in The Surgeon
- Vol. 15 (5) , 282-289
Intra-operative techniques to reduce the risk of capsular contracture in patients undergoing aesthetic breast augmentation – A review
- 1 October 2017
- Published by Elsevier in The Surgeon
- Vol. 15 (5) , 282-289
Intra-operative techniques to reduce the risk of capsular contracture in patients undergoing aesthetic breast augmentation – A review
- Open Access
- 1 April 2016
- Published by Elsevier in The Breast
- Vol. 26, 149-150
Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?
- 1 April 2016
- Published by Elsevier in The Breast
- Vol. 26, 149-150
Open AccessTime for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?
- 14 January 2016
- Published by Mark Allen Group in British Journal of Nursing
- Vol. 25 (1) , 16-21
Recording inpatient weight: implications for medicines administration
To identify the proportions of hospital inpatients with recorded weights: among all patients, and among those receiving weight-dosed drug therapy. Survey of clinical notes of hospital inpatients across a convenience sample of 11 secondary and tertiary referral hospitals in England and Wales in November 2011. 1068 patients were included, and 1061 patient clinical notes were available (99.3%). Nearly all paediatric patients had recorded weights (77/78; 98.7%). Half of adult inpatients had recorded weights (503/983, 51.2%). The proportion of adult inpatients with recorded weights varied by hospital, ranging from 13.5% to 92.5% (p<0.0001). In those receiving gentamicin or therapeutic-dose low molecular weight heparin (t-LMWH), only 64.5% (71/110) had a recorded weight. Half of adult inpatients, and two-thirds of those receiving gentamicin or t-LMWH, had recorded weights. There was significant variation in rates of weighing adult inpatients across hospitals. This may put patients at increased risk of side effects and problems resulting from malnutrition.
- 14 January 2016
- Published by Mark Allen Group in British Journal of Nursing
- Vol. 25 (1) , 16-21
Recording inpatient weight: implications for medicines administration
To identify the proportions of hospital inpatients with recorded weights: among all patients, and among those receiving weight-dosed drug therapy. Survey of clinical notes of hospital inpatients across a convenience sample of 11 secondary and tertiary referral hospitals in England and Wales in November 2011. 1068 patients were included, and 1061 patient clinical notes were available (99.3%). Nearly all paediatric patients had recorded weights (77/78; 98.7%). Half of adult inpatients had recorded weights (503/983, 51.2%). The proportion of adult inpatients with recorded weights varied by hospital, ranging from 13.5% to 92.5% (p<0.0001). In those receiving gentamicin or therapeutic-dose low molecular weight heparin (t-LMWH), only 64.5% (71/110) had a recorded weight. Half of adult inpatients, and two-thirds of those receiving gentamicin or t-LMWH, had recorded weights. There was significant variation in rates of weighing adult inpatients across hospitals. This may put patients at increased risk of side effects and problems resulting from malnutrition.
- 1 September 2013
- Published by Royal College of Surgeons of England in The Annals of The Royal College of Surgeons of England
- Vol. 95 (6) , 443-444
Rectus sheath catheterisation: a novel method of placement
- 1 September 2013
- Published by Royal College of Surgeons of England in The Annals of The Royal College of Surgeons of England
- Vol. 95 (6) , 443-444
Rectus sheath catheterisation: a novel method of placement
- 4 February 2013
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 45 (S 02) , E299-E300
A strangulated hernia as a result of ERCP
An 83-year-old woman attended for endoscopic retrograde cholangiopancreatography (ERCP) following an episode of acute jaundice. A computed tomography (CT) scan confirmed a dilated common bile duct with a distal filling defect that was later confirmed on magnetic resonance imaging (MRI) to be a biliary stone. She had undergone a right inguinal hernia repair 5 years previously and the CT scan suggested a possible recurrence ([Fig. 1]). Sphincterotomy was performed at ERCP and a 10-mm stone was extracted. On the first postoperative day, she developed a temperature of 38.5 °C and produced a feculent vomit. A plain abdominal radiograph showed distended small-bowel loops. Her arterial blood gases were normal but her white cell count was elevated at 16.2 × 109/L, as was her C-reactive protein (CRP) at 268 mg/L. A repeat CT scan revealed an incarcerated inguinal hernia causing small-bowel obstruction ([Fig. 2]). She underwent an emergency laparotomy, which revealed the strangulated hernia ([Fig. 3 a]) with a segment of necrotic small bowel 270 cm from the ligament of Treitz ([Fig. 3 b]). This segment was resected using a linear stapler to create a stapled side-to-side anastomosis. The patient recovered well and was fit for discharge 4 days later. During any endoscopic procedure visualization of the lumen is achieved by the insufflation of gas. However, because ambient “room air” is not well absorbed by the gastrointestinal tract, it must either be suctioned at the end of the procedure or be passed through the gastrointestinal tract as flatus [1]. ERCP can lead to prolonged examination time and overinsufflation [2]. More pertinently it may cause bowel hyperextension limiting the flexibility of the endoscope. It has previously been reported that this may cause barotrauma resulting in perforation or abdominal compartment syndrome [1]. Carbon dioxide is better absorbed by the bowel and has been shown to reduce pain both during and after the procedure, as well as sedation requirements and procedure and recovery times [3]. We suggest that the presence of any abdominal hernias is documented when carrying out a prolonged endoscopic procedure such as an ERCP. Also, in such cases judicious use of room air or carbon dioxide insufflation should be considered to prevent the conversion of an incarcerated to a strangulated hernia as in this case. Endoscopy_UCTN_Code_CPL_1AK_2AJ
- 4 February 2013
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 45 (S 02) , E299-E300
A strangulated hernia as a result of ERCP
An 83-year-old woman attended for endoscopic retrograde cholangiopancreatography (ERCP) following an episode of acute jaundice. A computed tomography (CT) scan confirmed a dilated common bile duct with a distal filling defect that was later confirmed on magnetic resonance imaging (MRI) to be a biliary stone. She had undergone a right inguinal hernia repair 5 years previously and the CT scan suggested a possible recurrence ([Fig. 1]). Sphincterotomy was performed at ERCP and a 10-mm stone was extracted. On the first postoperative day, she developed a temperature of 38.5 °C and produced a feculent vomit. A plain abdominal radiograph showed distended small-bowel loops. Her arterial blood gases were normal but her white cell count was elevated at 16.2 × 109/L, as was her C-reactive protein (CRP) at 268 mg/L. A repeat CT scan revealed an incarcerated inguinal hernia causing small-bowel obstruction ([Fig. 2]). She underwent an emergency laparotomy, which revealed the strangulated hernia ([Fig. 3 a]) with a segment of necrotic small bowel 270 cm from the ligament of Treitz ([Fig. 3 b]). This segment was resected using a linear stapler to create a stapled side-to-side anastomosis. The patient recovered well and was fit for discharge 4 days later. During any endoscopic procedure visualization of the lumen is achieved by the insufflation of gas. However, because ambient “room air” is not well absorbed by the gastrointestinal tract, it must either be suctioned at the end of the procedure or be passed through the gastrointestinal tract as flatus [1]. ERCP can lead to prolonged examination time and overinsufflation [2]. More pertinently it may cause bowel hyperextension limiting the flexibility of the endoscope. It has previously been reported that this may cause barotrauma resulting in perforation or abdominal compartment syndrome [1]. Carbon dioxide is better absorbed by the bowel and has been shown to reduce pain both during and after the procedure, as well as sedation requirements and procedure and recovery times [3]. We suggest that the presence of any abdominal hernias is documented when carrying out a prolonged endoscopic procedure such as an ERCP. Also, in such cases judicious use of room air or carbon dioxide insufflation should be considered to prevent the conversion of an incarcerated to a strangulated hernia as in this case. Endoscopy_UCTN_Code_CPL_1AK_2AJ
- 1 June 2012
- Published by Elsevier in The Surgeon
- Vol. 10 (3) , 123-127
Raman spectroscopy – A potential new method for the intra-operative assessment of axillary lymph nodes
- 1 June 2012
- Published by Elsevier in The Surgeon
- Vol. 10 (3) , 123-127
Raman spectroscopy – A potential new method for the intra-operative assessment of axillary lymph nodes